Literature DB >> 31266388

Metabolism of lysergic acid diethylamide (LSD): an update.

Rui Filipe Libânio Osório Marta1,2.   

Abstract

Lysergic acid diethylamide (LSD) is the most potent hallucinogen known and its pharmacological effect results from stimulation of central serotonin receptors (5-HT2). Since LSD is seen as physiologically safe compound with low toxicity, its use in therapeutics has been renewed during the last few years. This review aims to discuss LSD metabolism, by presenting all metabolites as well as clinical and toxicological relevance. LSD is rapidly and extensively metabolized into inactive metabolites; whose detection window is higher than parent compound. The metabolite 2-oxo-3-hydroxy LSD is the major human metabolite, which detection and quantification is important for clinical and forensic toxicology. Indeed, information about LSD pharmacokinetics in humans is limited and for this reason, more research studies are needed.

Entities:  

Keywords:  LSD; hallucinogens; metabolism; toxicity; toxicokinetics

Mesh:

Substances:

Year:  2019        PMID: 31266388     DOI: 10.1080/03602532.2019.1638931

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  6 in total

Review 1.  Neurotoxicology Syndromes Associated with Drugs of Abuse.

Authors:  Rachel A Caplan; Jonah P Zuflacht; Jed A Barash; Corey R Fehnel
Journal:  Neurol Clin       Date:  2020-11       Impact factor: 3.806

2.  Potential Treatment for Obsessive-Compulsive Disorder.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2022-09-01       Impact factor: 4.632

Review 3.  Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.

Authors:  Nicole L Galvão-Coelho; Wolfgang Marx; Maria Gonzalez; Justin Sinclair; Michael de Manincor; Daniel Perkins; Jerome Sarris
Journal:  Psychopharmacology (Berl)       Date:  2021-01-11       Impact factor: 4.530

Review 4.  Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.

Authors:  Paul Cumming; Milan Scheidegger; Dario Dornbierer; Mikael Palner; Boris B Quednow; Chantal Martin-Soelch
Journal:  Molecules       Date:  2021-04-22       Impact factor: 4.411

5.  Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD.

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Benedikt Pulver; Hannes M Schwelm; Kyla Whitelock; Alexander Stratford; Volker Auwärter; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2022-05-29       Impact factor: 3.234

Review 6.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.